Covaccine, along with Covishield, was first introduced in India in January as a vaccine to fight the pandemic. But here, the World Health Organization (WHO) has further delayed the Emergency Use Authorization (EUA) for the Covid vaccine developed in India. For this, WHO has sent more technical questions to Bharat Biotech. This delay is likely to impact the international travel plans of Indians, especially students.
Explain that without the EUA, Covaxin would not be considered a vaccine approved by most countries around the world. Bharat Biotech claims that it has sent all the necessary documents, yet WHO has sent these queries. Earlier there was news that WHO will approve it soon but now there are signs of delay.
According to an ANI report, Dr Bharti Praveen Pawar, Union Minister of State in the Ministry of Health had said last Friday, “There is a process to submit documents for approval. Covaxin is expected to get emergency use authorization from WHO soon.”
Earlier, Dr VK Paul, chairman of the National Expert Group on Vaccine Administration, had also said that the WHO approval for Covaxin is likely to come before the end of this month. According to Bharat Biotech, the Phase III clinical trial of Covaxin had demonstrated an efficacy rate of 77.8 percent.
Let us inform that Covaxin, Covishield was first included in the nationwide vaccination campaign in January this year against COVID-19. Others, such as the Russian-made Sputnik, came to the country only later.